Featured

Featured posts

Time to put a stop to the abuse of orphan drug regulation- the latest...

Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...

Never say never – Why the High Income Countries that opted-out from the Art....

To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...

Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...

The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...

Drug Price Transparency Calls Move from South Africa to World Health Assembly

by Katrina Perehudoff and Jennifer Sellin Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...

Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands honour for her...

Ellen 't Hoen has been appointed Officer of the Order of Oranje-Nassau, a royal award which recognises those who merit particular appreciation from society...

“The diseases were in the South and the drugs were in the North”: Ellen...

Ellen 't Hoen discusses the HIV epidemic in the 90's, which hit sub-Saharan Africa particularly hard, and was exacerbated by the lack of availability...

BMJ Commentary: Overriding drug and medical technology patents for pandemic recovery: a legitimate move...

Interest in the use of compulsory licensing is making a comeback in high-income countries in response to concerns about access to Covid-19 vaccines and...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...

With technology transfer, 120 companies in low- and middle-income countries could manufacture mRNA vaccines

Recent reporting from the British Medical Journal (BMJ) has revealed efforts by BioNTech – the technology firm behind Pfizer’s projected $100 billion in Covid-19...

Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...

This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....